{"filing":{"accession_number":"0001628280-26-057988","cik":"0001898416","ticker":"ALVOW","company_name":"Alvotech","form":"6-K","filing_date":"2026-08-19","report_date":"2026-06-30","primary_document":"alvo-20260630_d2.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1898416/000162828026057988/alvo-20260630_d2.htm"},"events":[{"id":28557,"run_id":26128,"accession_number":"0001628280-26-057988","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release announcing Alvotech's financial results for the first half of 2026, including adjusted total revenue of $211.9 million (down 30.8% YoY), adjusted EBITDA of $46.9 million, and cash balance of $142.8 million. The disclosure includes H1 2026 financial highlights, Q2 business highlights (FDA resubmissions, facility inspection results, equity financing), CEO commentary, and full-year 2026 guidance ($650-700M revenue, $180-220M adjusted EBITDA). This is a discrete earnings announcement, not a periodic financial report filing, and is material to investors assessing the company's financial performance and regulatory progress.","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-08-19","form":"6-K","submitted_at":null,"items":[{"id":30542,"accession_number":"0001628280-26-057988","item_number":"EX-99.3","item_title":"earningsreleaseq22026.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Alvotech's financial results for the first half of 2026, including adjusted total revenue of $211.9 million (down 30.8% YoY), adjusted EBITDA of $46.9 million, and cash balance of $142.8 million. The disclosure includes H1 2026 financial highlights, Q2 business highlights (FDA resubmissions, facility inspection results, equity financing), CEO commentary, and full-year 2026 guidance ($650-700M revenue, $180-220M adjusted EBITDA). This is a discrete earnings announcement, not a periodic financial report filing, and is material to investors assessing the company's financial performance and regulatory progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:35:48.712611+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30540,"accession_number":"0001628280-26-057988","item_number":"EX-99.1","item_title":"alvo-20260630.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an unaudited condensed consolidated interim financial statement for the six months ended 30 June 2026, clearly labeled as such in the header. It presents interim financial statements (balance sheet, income statement, cash flows, and changes in equity) for a foreign private issuer, which is the periodic financial report itself rather than a discrete event or earnings press release. The document is the XBRL-tagged financial report, not a results announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:35:48.712611+00:00","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-08-19"},{"id":30541,"accession_number":"0001628280-26-057988","item_number":"EX-99.2","item_title":"mdaq22026.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is Alvotech's Management's Discussion and Analysis (MD\u0026A) accompanying unaudited condensed consolidated interim financial statements for the six months ended 30 June 2026. The document explicitly states it should be read \"together with our unaudited condensed consolidated interim financial statements\" and discusses financial results for the interim period. This is a periodic interim financial report, not a discrete event or earnings release press announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:35:48.712611+00:00","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-08-19"},{"id":30542,"accession_number":"0001628280-26-057988","item_number":"EX-99.3","item_title":"earningsreleaseq22026.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Alvotech's financial results for the first half of 2026, including adjusted total revenue of $211.9 million (down 30.8% YoY), adjusted EBITDA of $46.9 million, and cash balance of $142.8 million. The disclosure includes H1 2026 financial highlights, Q2 business highlights (FDA resubmissions, facility inspection results, equity financing), CEO commentary, and full-year 2026 guidance ($650-700M revenue, $180-220M adjusted EBITDA). This is a discrete earnings announcement, not a periodic financial report filing, and is material to investors assessing the company's financial performance and regulatory progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:35:48.712611+00:00","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-08-19"}]}